Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Window of Opportunity Trial of Cetuximab in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Trial Profile

A Window of Opportunity Trial of Cetuximab in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2019

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2019 Planned End Date changed from 1 Jan 2023 to 1 Mar 2023.
    • 15 Feb 2019 Planned primary completion date changed from 1 Jan 2022 to 1 Mar 2022.
    • 15 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top